Stay updated with breaking news from Global External. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Cash position1 at €87.2 million as of June 30, 2022, compared to €95.4 million as of December 31, 2021 Receipt of a €4 million milestone payment from Inventiva's partner AbbVie for cedirogant Phase IIb
Investegate announcements from INVENTIVA, Inventiva reports its 2022 first-half financial results and provides a corporate update
Investegate announcements from INVENTIVA, Inventiva and Sino Biopharm announce licensing and collaboration agreement to develop and commercialize lanifibranor in Greater China
Sino Biopharm a leading Chinese pharmaceutical group, through CTTQ will oversee the development and commercialization of lanifibranor in Greater ChinaLanifibranor is an orally-available small molecule
Daix (France), Long Island City (New York, United States), September 7, 2022 - Inventiva (Euronext Paris and Nasdaq: IVA) (the "Company"), a clinical-stage biopharmaceutical company focused on the development